HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Down 2.6%

ACXP stock traded down $0.04 during trading on Tuesday, reaching $1.31. The company’s stock had a trading volume of 161,646 shares, compared to its average volume of 1,112,354. Acurx Pharmaceuticals has a 1 year low of $1.27 and a 1 year high of $8.34. The company has a market capitalization of $7.26 million, a P/E ratio of -0.49 and a beta of -2.02. The company’s fifty day moving average is $1.43 and its 200-day moving average is $2.08.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). Analysts anticipate that Acurx Pharmaceuticals will post -2 earnings per share for the current year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.